Japan Disposes Billions Worth of COVID-19 Pills
(MENAFN) Japan’s Ministry of Health announced on Wednesday that it had thrown away nearly 240 billion yen (about $1.6 billion) worth of oral COVID-19 treatments during the financial year concluding in March.
This move came after the expiration of the drugs’ shelf lives, as noted by a news agency.
These antiviral medications — originally acquired to serve approximately 2.5 million individuals — were bought during the peak of the pandemic and distributed at no cost to medical facilities across the nation.
Nevertheless, a large portion of the drugs remained untouched after the government decided in May 2023 to reclassify COVID-19 as a disease similar in status to the common flu.
This policy adjustment transferred the financial responsibility for treatment from the government to individual patients.
Information from the Ministry of Health, Labor and Welfare indicated that the discarded supply included 1.75 million courses of Pfizer’s nirmatrelvir and 780,000 doses of Merck’s molnupiravir.
In addition, the authorities procured 2 million courses of ensitrelvir, manufactured by Shionogi & Co., though roughly 1.77 million remain unused.
These too are projected to be disposed of once they reach expiration, according to the same report.
By March 2024, it was estimated that over 70 million people in Japan had been infected with COVID-19.
As of the previous August, the nation had recorded approximately 132,000 deaths linked to the virus.
This move came after the expiration of the drugs’ shelf lives, as noted by a news agency.
These antiviral medications — originally acquired to serve approximately 2.5 million individuals — were bought during the peak of the pandemic and distributed at no cost to medical facilities across the nation.
Nevertheless, a large portion of the drugs remained untouched after the government decided in May 2023 to reclassify COVID-19 as a disease similar in status to the common flu.
This policy adjustment transferred the financial responsibility for treatment from the government to individual patients.
Information from the Ministry of Health, Labor and Welfare indicated that the discarded supply included 1.75 million courses of Pfizer’s nirmatrelvir and 780,000 doses of Merck’s molnupiravir.
In addition, the authorities procured 2 million courses of ensitrelvir, manufactured by Shionogi & Co., though roughly 1.77 million remain unused.
These too are projected to be disposed of once they reach expiration, according to the same report.
By March 2024, it was estimated that over 70 million people in Japan had been infected with COVID-19.
As of the previous August, the nation had recorded approximately 132,000 deaths linked to the virus.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- NOVA Collective Invest Showcases Intelligent Trading System7.0 Iterations Led By Brady Rodriguez
- VCUK Launches New Private Equity And Venture Capital Initiative With A Focus On Europe
- From Zero To Crypto Hero In 25 Minutes: Changelly Introduces A Free Gamified Crash Course
- Blackrock Becomes The Second-Largest Shareholder Of Freedom Holding Corp.
- Cartesian Launches First Outsourced Middle-Back-Office Offering For Digital Asset Funds
- Ethereum Based Meme Coin Pepeto Presale Past $6.7 Million As Exchange Demo Launches
Comments
No comment